Pfizer COVID-19 to PH vaccine proposal

Pharmaceutical giant Pfizer submitted its proposal to the Philippine government as the country offers to protect a vaccine source from foreign manufacturers, a Department of Health (DOH) official showed Saturday.

The Undersecretary of Health, María Rosario Vergeire, said senior officials of the US pharmaceutical corporation presented their proposal this Friday at an assembly with Secretary of Health Francisco Duque III and Secretary of Science and Technology, Fortunato de los Angeles Pea, however, revealed some main points about the situation.Discussions.

“The Philippines, through the Ministry of Health and the Secretariat of the Department of Science and Technology, has spoken to them on this issue.There will be a first array revision … So we still don’t have a definitive agreement with Pfizer,” he said.said in Filipino at the Laging Handa briefing.

It noted that the parties were implementing a confidentiality disclosure agreement for transparency.

“Once this is over, we’ll talk about the arrangement with them,” he said.

On Friday, DOH representatives also met practically with the Russian Embassy in Manila to discuss an upcoming assembly between the government and the Gamaleya Institute for Epidemiology and Microbiology Research, candidate vaccine developer Sputnik V.

It’s scheduled “next week or the next week,” Vergeire said.

Russia is the first country to pass a vaccine opposed to SARS-CoV-2, a resolution that has aroused the initial skepticism of the foreign community.At the time of approval on 11 August, the vaccine did not begin the Phase 3 clinical trial.

According to Sputnik V’s website, “post-registration clinical trials” began on 24 August with more than 40,000 people in Russia.Several countries, such as the United Arab Emirates, Saudi Arabia, the Philippines and, in all likelihood, India or Brazil, will be registered locally in Sputnik V clinical trials, he added.

Philippine News Agency

Leave a Comment

Your email address will not be published. Required fields are marked *